

Aptar Digital Health Partners with BioTrillion to Accelerate Detection and Monitoring of Neurological and Cardiological Conditions

Aptar Digital Health, a global leader in Software as a Medical Device (SaMD) and disease management solutions, and BioTrillion, Inc., an innovator applying Artificial Intelligence (AI) at the intersection of smartphone technology and human physiology, have announced a strategic partnership to accelerate detection and monitoring of neurological and cardiological conditions. The partnership will leverage the combined capabilities of the two organizations to support their pharmaceutical partners aiming to deliver enhanced patient experiences through innovative digital solutions.

BioTrillion has developed an innovative digital biomarker platform, BioEngine4D™, to accelerate disease detection and drug development. From a 10-second "HealthySelfie" face video, BioEngine4D™ applies its AI-powered computer vision to extract and measure five key vital signs and disease biomarkers including heart rate, blood pressure, pupil response, eye saccades, and hand tremor, demonstrating an average accuracy over 90% relative to standard of care in validation testing on human subjects. BioTrillion's software-only platform unlocks the powerful optical hardware in a smartphone, already in the hands of 5 billion people globally, to enable scalable and accessible health monitoring—without the need for additional physical attachments or hardware. BioTrillion extends its innovation into combinatorial analyses of these five vital signs to offer powerful insights into a range of neurology and cardiology indications. Healthcare organizations can easily access BioTrillion's interface from their user's smartphone, uploading "video for vitals," providing real-time, actionable health data for applications across the healthcare industry—from early disease detection to accelerated drug development.

The collaboration will integrate Aptar Digital Health's platform with BioTrillion's AI-powered BioEngine4D™ platform to provide pharmaceutical companies with a comprehensive solution for drug effect and disease response data, objective and quantitative endpoints, and accelerated drug development, across multiple indications such as Parkinson's disease, hypertension, and movement disorders.

Aptar Digital Health and BioTrillion will work closely with pharmaceutical partners to create tailored solutions that enhance clinical trial precision and deliver personalized treatment pathways. The combined

solution will allow life science companies to leverage digital biomarkers in multiple therapeutic areas, ensuring improved disease detection and monitoring.

Sai Shankar, President of Aptar Digital Health, stated, “We are excited to partner with BioTrillion to deploy existing and co-develop new opportunities to expand our integrated platform, offering the most comprehensive digital biomarker platform for conditions in neurology and cardiology. This partnership will help our partners address limitations of real-world intervention, with digital solutions supporting drug development, and more.”

Savan Devani, CEO of BioTrillion, said, “This strategic partnership with Aptar Digital Health will empower pharmaceutical companies with digital solutions that will redefine measures and endpoints to be more objective and quantitative across multiple neurological and cardiological conditions. By combining our technologies, we can improve patient outcomes by advancing healthcare’s approach to disease detection and drug development, at digital speed and scale.”

Pharma partners interested in exploring how these integrated solutions can redefine their clinical trials and treatment approaches are encouraged to reach out to Aptar Digital Health using the Contact Us tab.